Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials; Japanese conglomerate to buy Calliditas Therapeutics, maker of a kidney disease drug

Taking stock of the drug industry, from the lab to the medicine chest

May 28, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Airway disease drug from Insmed succeeds in one of the year's most anticipated trials The trial of the drug, called brensocatib, in a disease that causes airway problems has been one of the most closely watched this year. By Andrew Joseph STAT+ | Japanese conglomerate to buy Calliditas Therapeutics, maker of a kidney disease drug Calliditas, a Swedish biotech, has an approved drug called Tarpeyo that treats a rare kidney disease called IgA nephropathy. By Andrew Joseph STAT+ | Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer The Merus drug has generated attention, particularly from biotech investors, for its potential to improve head and neck cancer treatment. By Adam Feuerstein Dr. Edwin P. Ewing, Jr./CDC STAT+ | Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of Duchenne drugs. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser